In the crosshairs of the latest controversy on whether a drug is spurious or “not of standard quality” is the Indian patient. The pharma industry suffered a body blow recently after government agencies pulled up over 50 popular medicine brands. How do patients trust their medicines?
Related Posts
This Ranjan Pai investment opens the door to a USD30 billion opportunity
Ranjan Pai is among India’s most influential investors. So, when he makes a move into senior care, it is time…
narayana hrudayalaya: Narayana Hrudayalaya’s shares are on a growth beat. What’s driving the hospital chain’s optimism?
Synopsis Improving financials of hospital chains, future growth prospects of the sector itself have attracted investors to hospital stocks. But…
us shark tank: Selling cut-price generics, Mark Cuban is shaking up US pharma. Can Indian drug makers benefit?
Getty Images Mark Cuban. Synopsis Most of the large Indian pharma companies earn a big chunk of their revenue by…
